Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Moderna, Inc. Director's Dealing 2019

Nov 22, 2019

30610_dirs_2019-11-22_ab6f455a-883d-4542-8d53-7eb64dbeaa14.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2019-11-20

Reporting Person: HUTT PETER BARTON (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2019-11-20 Common Stock M 200000 $.04 Acquired 203924 Direct
2019-11-20 Common Stock S 200000 $20.18 Disposed 3924 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2019-11-20 Stock Option (Right to Buy) $.04 M 200000 Disposed 2022-03-27 Common Stock (200000) Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. The shares sold in multiple transactions at prices ranging from $20.00 to $20.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F2: This option is fully vested and exercisable.